Evotec SE Return on Equity

Evotec SE (EVO) currently reports a ROE of -30.04%. That is below the Healthcare sector average of 20.77%. Use the charts on this page to explore Evotec SE's ROE history and peer comparisons.

Evotec SE's ROE of -30.04% is lower than the Healthcare sector average of 20.77%. That is roughly 244.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Evotec SE's current -30.04% should be judged against Healthcare norms (sector average: 20.77%) and against EVO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -30.04%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.77%. From there, open related valuation or income-statement pages for Evotec SE, and consider following EVO for alerts when major investors trade the stock.

Evotec SE is classified in the Healthcare sector. On ROE, it currently shows -30.04% versus a sector average near 20.77%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EVO with unrelated industries.